Inhibiting RAD52 induces synthetic lethality in many cancer cells with defective DNA repair-related proteins, such as BRCA1, BRCA2, PALB2, XAB3, and RAD51 paralogues (i.e., RAD51B, RAD51C, RAD51D, XRCC2, XRCC3) [9,10,99,100]. This evidence concerns the gene BRCA2 and cancer.